Prospective Study of Cysteamine in the Treatment of Melasma

Authors

DOI:

https://doi.org/10.9771/cp.v12i5.32566

Keywords:

Cysteamine, Melasma, Technological Prospection.

Abstract

The treatment of melasma, a pigmentary disorder characterized by dark patches on the skin, is difficult and time-consuming because there is no cure, only control. According to the latest studies in the field of dermatology, Cysteamine is an active agent that acts as a pigment broker, reducing the melanin of the skin, correcting melasma and hyperpigmentation of the skin. Cysteamine is a depigmentant, a bleaching agent with an antioxidant effect. Thus, this study aimed to conduct a survey of information on patents related to the use of Cysteamine as a skin depigmenter with melasma. It was used the patent Mapping, Bibliographic Survey and Discussion of literature . It was noticed that there is low production of articles published in Brazil, with foreign authors being the ones who publish the most on the subject researched. As in the international databases, the search result brought the different ways of using Cysteamine, not only in dermatology, but for capillary treatment, infections caused by fungi and viruses, diabetes, cystinosis, among others. However, specifically to treat melasma, there is still no record in Brazil.

Downloads

Download data is not yet available.

Author Biographies

Marília Dione Salvador Shibayama, Federal University of Amapá, Macapá, AP, Brazil

Master's student in Intellectual Property and Technology Transfer for Innovation - PROFNIT (2019-2021). Specialist in Information Management in Digital Libraries from the Federal University of Pará - UFPA (2009). Graduated in Librarianship from UFPA (2002). She is Librarian-Documentalist at the Federal University of Amapá - UNIFAP. He works at the Documentation and Special Programs Division - DDPE, at the Central Library of the Marco Zero campus. Division responsible for the organization, technical treatment and dissemination of the scientific production of the academic works of doctorates, masters, specialization and graduation of the University, as well as other special materials, such as multimedia, maps, scientific journals, photographs, ABNT Online Collection, Biomedical & Life Science, in addition to providing training on the CAPES Periodicals Portal for the internal and external academic community. He was head of DDPE from March 2016 to March 2018. He has experience in the area of ​​Librarianship, with emphasis on University Libraries, Public Libraries, Technical Education Libraries, Children's Libraries and Legal Archives.

Geraldo Neves de Albuquerque Maranhão, Federal University of Amapá, Macapá, AP, Brazil

He holds a degree in Electrical Engineering from the Federal University of Pará (2005), a Master's degree in Electrical Engineering from the Federal University of Pará (2006) and a PhD in the Postgraduate Program in Electrical Engineering from the Federal University of Pará (2015). He is currently a professor at the Federal University of Amapá. He has experience in Electrical Engineering, with emphasis on Industrial Electronics, Sensors, Electronic Systems and Controls, Photovoltaic Systems, Systems Optimization and Computational Intelligence.

Werbeston Douglas de Oliveira, Federal University of Amapá, Macapá, AP, Brazil

Professor at the Federal University of Amapá (2017). He holds a degree, master's and doctorate in Electrical Engineering from the Federal University of Pará (2011), (2013) and (2017), respectively, with an emphasis on Electric Power Systems. He is currently the leader of the UNIFAP Energy Systems Studies group. He has experience in the area of ​​Electrical Engineering, with an emphasis on electrical energy generation, electrical systems safety, applied data mining in power systems, stability and distributed generation, working as a researcher at the Laboratory of Modeling and Simulation of Electrical Power Systems at the Center of Excellence in Energy Efficiency in the Amazon (CEAMAZON). IEEE Membership, IEEE Power & Energy Society.

References

CESTARI, T.; PERUZZO, J.; GIONGO, N. Definition, incidence and etiology of melasma in brown skin. In: Melasma and vitiligo in brown skin. Springer, New Delhi, 2017. p. 13-19.

CISTEAMINA HCL: ativo clareador para controle do melasma. Primacêutica, 2018. Disponível em: http://www.primaceutica.com.br/wp-content/uploads/2019/04/Cisteamina-HCL.pdf. Acesso em: 02 jul. 2019.

DREHMER, Raquel. Cisteamina e microagulhamento: o que há de novo no tratamento para melasma. Revista MdeMulher, 2019. Disponível em: https://mdemulher.abril.com.br/saude/cisteamina-e-microagulhamento-o-que-ha-de-novo-no-tratamento-para-melasma/. Acesso em: 14 de jul. 2019.

GHEISARI, Mehdi; DADKHAHFAR, Sahar; OLAMAEI, Elham. The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled Trial. Journal of Cosmetic Dermatology, 2019. Disponível em: https://onlinelibrary-wiley.ez7.periodicos.capes.gov.br/doi/full/10.1111/jocd.12987. Acesso em: 19 jul. 2019.

GRIMES, P. E.; IJAZ, S.; NASHAWATI, R. New oral and topical approaches for the treatment of melasma. International Journal of Women's Dermatology, v. 5, p. 30–36, 2019. Disponível em: https://www-sciencedirect.ez7.periodicos.capes.gov.br/journal/international-journal-of-womens-dermatology/vol/5/issue/1. Acesso em: 14 jul. 2019.

HSU, Christophe; MAHDI, Hussain Ali; POURAHMADI, Mohammad. Cysteamine cream as a new skin depigmenting product. Journal of the American Academic of Dermatology, v. 68, n. 4, 2013. Disponível em: https://www.jaad.org/article/S0190-9622(12)02060-9/abstract. Acesso em: 14 jul. 2019.

HUERTH, Kimberly; SHAHZEB, Hassan; CALLENDER, Valerie. Therapeutic insights in melasma and hyperpigmentation management. Journal of Drugs in Dermatology, v. 18, n. 8, p. 718-729, ago. 2019. Disponível em: https://jddonline.com/articles/dermatology/S1545961619P0718X/1/. Acesso em: 2 set. 2019.

INSTITUTO NACIONAL DE PROPRIEDADE INDUSTRIAL – INPI. Disponível em: http://www.inpi.gov.br/. Acesso em: 16 jul. 2019.

KASRAEE, Behrooz; MANSOURI, Parvin; FARSHI, Susan. Significant therapeutic response to cysteamine cream in a melasma patient resistant to Kligman's formula. Journal of Cosmetic Dermatology, v. 18, n. 1, p. 293(3), 2019. Disponível em: https://onlinelibrary-wiley.ez7.periodicos.capes.gov.br/doi/full/10.1111/jocd.12837. Acesso em: 15 jul. 2019.

MAGALHÃES, Cláudia. O que há de novo em melasma segundo o Meeting AAD 2018?. 2018. Disponível em: https://noticias.ne10.uol.com.br/coluna/questao-de-pele/noticia/2018/02/28/o-que-ha-de-novo-em-melasma-segundo-o-meeting-aad-2018-723241.php. Acesso em: 12 jul. 2019.

MANSOURI, P.; FARSHI, S.; HASHEMI, Z. Evaluation of the efficacy of cysteamine 5% cream in the treatment of epidermal melasma: a randomized double‐blind placebo‐controlled Trial. British Journal of Dermatology, v. 173, n. 1, p. 209-2017, 2015. Disponível em: https://onlinelibrary-wiley.ez7.periodicos.capes.gov.br/doi/full/10.1111/bjd.13424. Acesso em: 15 jul. 2019.

MANSOURI, P.; FARSHI, S.; HASHEMI, Z. Efficacy of cysteamine cream in the treatment of epidermal melasma, evaluating by Dermacatch as a new measurement method: a randomized double blind placebo controlled study. Journal of Dermatological Treatment, v. 29, n. 2, p.182-190, 2018. Disponível em: https://www.unboundmedicine.com/medline/citation/28678558/Efficacy_of_cysteamine_cream_in_the_treatment_of_epidermal_melasma_evaluating_by_Dermacatch_as_a_new_measurement_method:_a_randomized_double_blind_placebo_controlled_study_. Acesso em: 15 jul. 2019.

MEDICAMENTO: cisteamina é novidade para melasma. Folha Vitória, maio 2019. Disponível em: https://www.folhavitoria.com.br/saude/noticia/05/2019/medicamento-cisteamina-e-novidade-para-melasma. Acesso em: 10 jul. 2019.

MUNOZ, Begona Escutia; ESTEBANEZ, Esther Quecedo; ESTRADA, Rafael Botella. Tratamiento del melasma. Piel, v. 25, n. 07, p. 405 – 410, 2010. Disponível em: https://www-sciencedirect.ez7.periodicos.capes.gov.br/search/advanced?docId=10.1016/j.piel.2010.01.005. Acesso em: 19 jul. 2019.

- RED DE REPOSITÓRIOS LATINO AMERICANOS. Disponível em: https://repositorioslatinoamericanos.uchile.cl/. Acesso em: 11 jul. 2019.

SARAIVA, Luciana; NASCIMENTO, Mayara; FILIPPO, Alexandre. Tratamento de melasma facial com associação do microagulhamento robótico e drug delivery de ácido tranexâmico. Surgical and Cosmetic Dermatology, v. 10, n. 4, 2018. Disponível em: http://www.surgicalcosmetic.org.br/detalhe-artigo/685/Tratamento-de-melasma-facial-com-associacao-do-microagulhamento-robotico-e-drug-delivery-de-acido-tranexamico. Acesso em: 01 jul. 2019.

SITONIO, Renata. Congressos internacionais de dermatologia apresentam cisteamina como arma poderosa para tratar melasma. Newslab, ano 25, ago./set. 2018. Disponível em: https://https://newslab.com.br/congressos-internacionais-de-dermatologia-apresentam-cisteamina-como-arma-poderosa-para-tratar-melasmas/. Acesso em: 05 jul. 2019.

TACKLING MELASMA. 2017. Disponível em: skingab.com/tackling-melasma/. Acesso em: 1º jul. 2019.

VARELLA, Maria Helena. Melasma: doenças e sintomas. Disponível em: https://drauziovarella.uol.com.br/doencas-e-sintomas/melasma/. Acesso em: 1º set. 2019.

Downloads

Published

2019-12-30

How to Cite

Shibayama, M. D. S., Maranhão, G. N. de A., & Oliveira, W. D. de. (2019). Prospective Study of Cysteamine in the Treatment of Melasma. Cadernos De Prospecção, 12(5), 1488. https://doi.org/10.9771/cp.v12i5.32566

Issue

Vol. 12 No. 5 (2019): Edição Especial - IX ProspeCT&I 2019 - Congresso Internacional do PROFNIT/FORTEC

Section

Prospecções Tecnológicas de Assuntos Específicos

License

Copyright (c) 2020 Cadernos de Prospecção

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos. Licença Creative Commons
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.